Profectus Biosciences to Present at Key Investor Conference in January 2010

Share Article

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral infections, announced today that the company will present at the upcoming Biotech Showcase investor conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco.

News Image

Past News Releases

RSS

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral infections, announced today that the company will present at the upcoming Biotech Showcase investor conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco. These conferences will provide strategic investment and partnering opportunities for Profectus, whose novel ProfectusVAX™ prime/boost vaccines and NF-kB small molecule programs continue to progress on the cutting edge of research and development.

Dr. John Eldridge, Chief Scientific Officer of Profectus BioSciences, commented, “It is an exciting time for vaccine development. Recent clinical data have validated both prime/boost vaccination and the use of therapeutic vaccines to treat chronic viral infections. The Profectus vaccine program has made excellent progress over the past year and will be initiating three proof-of-concept clinical trials in collaboration with the National Institutes of Health (NIH) in 2010. In addition, we have generated very positive preclinical results in our NF-kB small molecule program. We look forward to sharing these successful corporate and R&D results at these conferences, and reaching our clinical milestones in 2010.”

2010 Biotech Showcase, January 12-13, 2010, San Francisco, CA
Oral Presentation:
Who: Dr. John Eldridge
Title: Chief Scientific Officer
When: Wednesday, January 13, 9:40 AM
Where: Heritage Room, 10th Floor, Marines’ Memorial Club & Hotel
Website: http://www.biotechshowcase.com

About Profectus BioSciences Inc.
Profectus Biosciences is an innovative R&D clinical-stage vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. ProfectusVAX™, the Profectus proprietary vaccine approach combines its plasmid (p) DNA and rVSV (recombinant Vesicular Stomatitis Virus) vector platforms in a unique prime-boost strategy to enhance immune responses to viruses that cause chronic disease. Profectus has a pipeline of proprietary vaccine products to address diseases caused by Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), and Herpes Simplex Virus (HSV) as well as for Malaria. The first of three proof-of-concept clinical trials with the prime/boost HIV vaccine candidate is planned for H1 of 2010, followed by a therapeutic HCV vaccine.

The Profectus portfolio has secured over $100M in non-dilutive funding of its programs from multiple sources including the National Institutes of Health (NIH) and $19M in private equity financing, including Cross Atlantic Capital Partners (XACP). Profectus deploys these financial resources in support of its proprietary prime-boost vaccines for multiple indications. In addition, the Company is funding its early research small molecule program for potential partners. For more information, please visit: http://www.profectusbiosciences.com.

Contact:
Lisa Rivero
LaVoie Group
978-745-4200 x106
http://www.lavoiegroup.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Rivero
Visit website